CN100382844C - 可溶性β-淋巴毒素受体和抗淋巴毒素受体的抗体以及抗淋巴毒素配体的抗体的用途 - Google Patents

可溶性β-淋巴毒素受体和抗淋巴毒素受体的抗体以及抗淋巴毒素配体的抗体的用途 Download PDF

Info

Publication number
CN100382844C
CN100382844C CNB971999066A CN97199906A CN100382844C CN 100382844 C CN100382844 C CN 100382844C CN B971999066 A CNB971999066 A CN B971999066A CN 97199906 A CN97199906 A CN 97199906A CN 100382844 C CN100382844 C CN 100382844C
Authority
CN
China
Prior art keywords
purposes
antibody
sealer
cell
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB971999066A
Other languages
English (en)
Chinese (zh)
Other versions
CN1237910A (zh
Inventor
J·布朗宁
P·S·霍克曼
P·D·伦纳特
F·麦凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN1237910A publication Critical patent/CN1237910A/zh
Application granted granted Critical
Publication of CN100382844C publication Critical patent/CN100382844C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB971999066A 1996-10-25 1997-10-24 可溶性β-淋巴毒素受体和抗淋巴毒素受体的抗体以及抗淋巴毒素配体的抗体的用途 Expired - Fee Related CN100382844C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2906096P 1996-10-25 1996-10-25
US60/029,060 1996-10-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA200810082273XA Division CN101239186A (zh) 1996-10-25 1997-10-24 可溶性β-淋巴毒素受体(LT-β-R)融合蛋白的用途

Publications (2)

Publication Number Publication Date
CN1237910A CN1237910A (zh) 1999-12-08
CN100382844C true CN100382844C (zh) 2008-04-23

Family

ID=21847003

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB971999066A Expired - Fee Related CN100382844C (zh) 1996-10-25 1997-10-24 可溶性β-淋巴毒素受体和抗淋巴毒素受体的抗体以及抗淋巴毒素配体的抗体的用途
CNA200810082273XA Pending CN101239186A (zh) 1996-10-25 1997-10-24 可溶性β-淋巴毒素受体(LT-β-R)融合蛋白的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA200810082273XA Pending CN101239186A (zh) 1996-10-25 1997-10-24 可溶性β-淋巴毒素受体(LT-β-R)融合蛋白的用途

Country Status (26)

Country Link
EP (1) EP0954333B1 (no)
JP (1) JP4299887B2 (no)
KR (1) KR100584704B1 (no)
CN (2) CN100382844C (no)
AT (1) ATE331531T1 (no)
AU (1) AU726357B2 (no)
BG (1) BG63565B1 (no)
BR (1) BR9712670A (no)
CA (1) CA2269614A1 (no)
CZ (1) CZ142899A3 (no)
DE (1) DE69736244T2 (no)
DK (1) DK0954333T3 (no)
EA (1) EA002983B1 (no)
EE (1) EE05213B1 (no)
ES (1) ES2268727T3 (no)
HK (1) HK1025500A1 (no)
HU (1) HU226467B1 (no)
IL (1) IL129527A (no)
IS (1) IS5031A (no)
NO (1) NO328540B1 (no)
NZ (1) NZ335353A (no)
PL (1) PL190617B1 (no)
PT (1) PT954333E (no)
SK (1) SK55399A3 (no)
TR (1) TR199901636T2 (no)
WO (1) WO1998017313A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
CN1200733C (zh) * 1998-10-09 2005-05-11 拜奥根有限公司 阻断淋巴毒素β与其受体结合的物质在制备药物中的应用
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
BR0012006A (pt) * 1999-06-28 2002-03-12 Basf Ag Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr
DE19939653A1 (de) * 1999-08-13 2001-02-22 Thomas Huenig Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
DK1674575T3 (da) * 2000-04-12 2010-11-29 Jolla Inst Allergy Immunolog Ligand for Herpes simplex-indgangsmediator og fremgangsmåder til anvendelse
AU2003303339A1 (en) * 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
RU2486201C2 (ru) 2006-10-12 2013-06-27 Дженентек, Инк. Антитела к лимфотоксину-альфа
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
EP2435477A1 (en) * 2009-05-28 2012-04-04 Glaxo Group Limited Antigen-binding proteins
WO2019238966A1 (en) * 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102360196B1 (ko) 2019-10-30 2022-02-08 주식회사 친환경테크 다용도 시트 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013808A2 (en) * 1992-12-04 1994-06-23 Biogen, Inc. LYMPHOTOXIN-β, LYMPHOTOXIN-β COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013808A2 (en) * 1992-12-04 1994-06-23 Biogen, Inc. LYMPHOTOXIN-β, LYMPHOTOXIN-β COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF

Also Published As

Publication number Publication date
IL129527A0 (en) 2000-02-29
PL190617B1 (pl) 2005-12-30
NO991926D0 (no) 1999-04-22
BG63565B1 (bg) 2002-05-31
IL129527A (en) 2006-12-10
HUP9904516A2 (hu) 2000-05-28
JP2001502697A (ja) 2001-02-27
EE9900146A (et) 1999-12-15
EP0954333B1 (en) 2006-06-28
SK55399A3 (en) 2000-10-09
EA199900409A1 (ru) 2000-02-28
HU226467B1 (en) 2008-12-29
NZ335353A (en) 2000-09-29
DE69736244D1 (de) 2006-08-10
PT954333E (pt) 2006-10-31
KR20000052800A (ko) 2000-08-25
CN1237910A (zh) 1999-12-08
CA2269614A1 (en) 1998-04-30
CN101239186A (zh) 2008-08-13
NO328540B1 (no) 2010-03-15
TR199901636T2 (xx) 1999-09-21
HK1025500A1 (en) 2000-11-17
JP4299887B2 (ja) 2009-07-22
EE05213B1 (et) 2009-10-15
AU726357B2 (en) 2000-11-02
HUP9904516A3 (en) 2002-09-30
IS5031A (is) 1999-04-21
DE69736244T2 (de) 2007-05-31
CZ142899A3 (cs) 1999-07-14
NO991926L (no) 1999-06-25
WO1998017313A2 (en) 1998-04-30
AU5089698A (en) 1998-05-15
KR100584704B1 (ko) 2006-05-30
BR9712670A (pt) 1999-10-19
DK0954333T3 (da) 2006-10-23
WO1998017313A3 (en) 1998-07-30
ATE331531T1 (de) 2006-07-15
PL332972A1 (en) 1999-10-25
ES2268727T3 (es) 2007-03-16
EP0954333A2 (en) 1999-11-10
EA002983B1 (ru) 2002-12-26
BG103416A (en) 2000-01-31

Similar Documents

Publication Publication Date Title
CN100382844C (zh) 可溶性β-淋巴毒素受体和抗淋巴毒素受体的抗体以及抗淋巴毒素配体的抗体的用途
US10494416B2 (en) Methods of modulating immune responses using BCMA polypeptide
KR100912994B1 (ko) Ｎｋｇ２ｄ의 조절
EP2040730B1 (en) Modulation of nkg2d in hbv patients
CN102690350A (zh) 抗il-22ra抗体和结合伴侣以及在炎症中的使用方法
US8287874B2 (en) Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
KR20070095949A (ko) 자가면역 장애의 치료 방법
CN1891714B (zh) 单纯疱疹病毒进入介体的配体和使用方法
JP3657271B2 (ja) 病原性または日和見感染性生物に感染した哺乳動物の治療のための組成物
CN1798768B (zh) 抗il-22ra抗体和结合伴侣及其应用
WO2008014035A2 (en) Modulation of nkg2d and method for treating or preventing solid organ allograft rejection
Glass Regulation and function of the Fas and perforin lytic pathways in cytotoxic T lymphocyte-mediated cell death
Nochi MALDI plate and co-crystallized withoff.-cyano-4-hydrox-ycinnamic acid [27]. This plate was then loaded into the QSTAR Pulser i (Applied Biosystems) at Hitachi Science Systems (Ibaraki, Japan). Cloning of porcine epithelial cell adhesion molecules
MXPA99003801A (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080423

Termination date: 20131024